EMEA-002153-PIP01-17

Key facts

Active substance
  • fluticasone furoate
  • umeclidinium bromide
  • vilanterol trifenatate
Therapeutic area
Pneumology-allergology
Decision number
P/0076/2018
PIP number
EMEA-002153-PIP01-17
Pharmaceutical form(s)
  • Inhalation powder
  • pre-dispensed
Condition(s) / indication(s)
Treatment of asthma
Route(s) of administration
Inhalation use
Contact for public enquiries
GlaxoSmithKline Trading Services Limited
Tel. +44 02089903650
E-mail: eu.paediatric-plans@gsk.com
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating